Editas Medicine, Inc.
EDIT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650664
In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $386.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Editas Medicine, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $34.0K in total
- Insiders trading
- 3
- Net value
- −$34.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Editas Medicine, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ory Daniel Scott | EVP, Chief Medical Officer | – | Sep 9, 2026 | 1 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 61,660 | Sep 4, 2026 | 6 |
| Parison Amy | SVP, Chief Financial Officer | 13,839 | Sep 4, 2026 | 6 |
| O'Neill Gilmore Neil | CEO | 243,189 | Sep 4, 2026 | 5 |
| Ellinor Patrick Thomas II | Director | – | Aug 7, 2026 | 1 |
| Hirsch Andrew | Director | – | Jun 22, 2026 | 1 |
| Hopfield Jessica | Director | 67,700 | Jun 22, 2026 | 1 |
| Connaughton Bernadette | Director | – | Jun 22, 2026 | 1 |
| Scadden David | Director | – | Jun 22, 2026 | 1 |
| Levy Elliott M. | Director | – | Jun 22, 2026 | 1 |
| Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 112,720 | Mar 27, 2025 | 0 |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 133,354 | Dec 5, 2024 | 0 |
| Vaishnaw Akshay | Director | – | Jun 3, 2024 | 0 |
| Reeve Emma | Director | – | Jun 3, 2024 | 0 |
| Chatterjee Meeta | Director | – | Jun 3, 2024 | 0 |
| Eaton Bruce | EVP, CBO AND CTO | 74,791 | Dec 7, 2023 | 0 |
| Robertson Michelle | EVP, CHIEF FINANCIAL OFFICER | 106,610 | May 15, 2023 | 0 |
| Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | 65,559 | Feb 15, 2023 | 0 |
| Mullen James C | CEO | 75,898 | Apr 18, 2022 | 0 |
| Michaels Lisa Anne | EVP/Chief Medical Officer | 22,675 | Dec 23, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2024 (view filing) | Dec 3 | 2 days | O'Neill Gilmore NeilCEO | SSale | −1.62K | $2.08 | −$3.37K | −0.5%312.1K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −2.89K | $1.71 | −$4.94K | −4.0%70.2K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4 | 1 day | O'Neill Gilmore NeilCEO | SSale | −16.6K | $1.71 | −$28.4K | −5.3%295.5K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4 | 1 day | Lucera ErickEVP, CHIEF FINANCIAL OFFICER | SSale | −4.11K | $1.71 | −$7.03K | −3.5%112.7K after | 10b5-1 |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −15.2K | $1.72 | −$26.1K | −5.1%280.3K after | 10b5-1 |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −726 | $1.72 | −$1.25K | −1.0%69.5K after | 10b5-1 |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −446 | $1.72 | −$767.12 | −2.5%17.5K after | 10b5-1 |
| Aug 4, 2025 (view filing) | Jul 31 | 4 days | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −5.12K | $2.49 | −$12.8K | −7.4%64.4K after | 10b5-1 |
| Aug 8, 2025 (view filing) | Aug 7 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −679 | $2.58 | −$1.75K | −3.9%16.8K after | 10b5-1 |
| Sep 4, 2025 (view filing) | Sep 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.59K | $2.60 | −$14.5K | −2.0%274.7K after | 10b5-1 |
| Sep 4, 2025 (view filing) | Sep 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −458 | $2.60 | −$1.19K | −2.7%16.4K after | 10b5-1 |
| Sep 4, 2025 (view filing) | Sep 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −710 | $2.60 | −$1.85K | −1.0%69.5K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −461 | $2.15 | −$991.15 | −2.8%15.9K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.60K | $2.15 | −$12.0K | −2.0%269.1K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −713 | $2.15 | −$1.53K | −1.0%68.8K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −749 | $2.02 | −$1.51K | −1.1%68.0K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −474 | $2.02 | −$957.48 | −3.0%15.4K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.39K | $2.02 | −$10.9K | −2.0%263.7K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −731 | $2.70 | −$1.97K | −1.1%67.3K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | O'Neill Gilmore NeilCEO | SSale | −15.4K | $2.70 | −$41.5K | −5.8%248.3K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Parison AmySVP, Chief Financial Officer | SSale | −464 | $2.70 | −$1.25K | −3.0%15.0K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:51 PM ET | Jul 28 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −4.93K | $2.67 | −$13.2K | −7.3%62.4K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:07 PM ET | Aug 3 | 2 days | Parison AmySVP, Chief Financial Officer | SSale | −678 | $2.58 | −$1.75K | −4.5%14.3K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:22 PM ET | Sep 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.12K | $3.04 | −$15.6K | −2.1%243.2K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −453 | $3.04 | −$1.38K | −3.2%13.8K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:27 PM ET | Sep 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −709 | $3.04 | −$2.15K | −1.1%61.7K after | 10b5-1 |